Monthly Archives: December 2020

SINGAPORE, Dec. 30, 2020 /PRNewswire/ -- Psoriasis causes skin cells to multiply up to 10 times faster than normal,causing skin build up into red patches covered with white scales affecting largely the scalp, elbows and knees. It is estimated that more than 125 million of the world's population is affected by this condition and people of Caucasian descent is 4 times more likely to contract this condition than Asian. Up to 60% of people with Psoriasis, particularly with women and younger patients, reported that their condition has a negative social impact in their lives. Whilst there is no cure available for Psoriasis, it is shown that topical agents when applied directly can bring this condition under control.

QTH Group is one ofthree company groups that specializes in Psoriasis, hence their products are produced with a specific target at this condition. QTH has a team of 50 dermatologists and over 100 researchers behind their range of products specifically produced to help people who suffer from Psoriasis. QTHrange of products are 100% natural, only using plant extracts. No animal ingredients or testing are used in the process of production.

QTH is pleased to announce the launch of their product range to the American market. Their product range consist of shampoo, scalp essence, body scrub,body lotionand anti-acne cream. All products are meant for topical use and application, the best methodology that is proven to be effective for this condition. The key ingredients that runs through their products is the right percentage blend of Salicylic Acid, which is extracted from white willow. QTH team of specialists have discovered that the right percentage of Salicylic Acid,used as one of the main ingredients,iskey to faster rate of relief and recovery.

Other key ingredients such as Argan Oil is used in QTHscalp essence and itis known for its healing and anti-inflammatory properties. Dead Sea Salt, known for their antifungal and antibacterial properties, is used in QTHbody scrub.

QTH'svision is to make their productsreadily available to all who needsthem.Hence, the sourcing of ingredients and production, whilst not compromising the high standards of productions, cost are kept efficient, to enable affordability. QTH products are available on https://www.amazon.com/qthand https://www.amazon.com/dp/B08MBM9RQ1

Media Contact ELPIS @ Hideout Pte LtdMs Lily Low[emailprotected](65) 82283339

SOURCE QTH Health

Read the rest here:
QTH Introduces Revolutionary Hair and Body Products for Effective Control of Psoriasis - PRNewswire

News Release

Monday, December 28, 2020

Psoriasis, a chronic inflammatory skin disease, has long been known to increase the risk of cardiovascular disease, which includes heart attack and stroke. Now, researchers have identified a key culprit: the presence of metabolic syndrome (MetSyn), a condition that includes obesity, diabetes, high cholesterol, and hypertension, and is highly prevalent among psoriasis patients.

The findings, which could lead to new ways to help prevent cardiovascular disease among people with psoriasis, appear online today in the Journal of the American Association of Dermatology (JAAD). The study was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Metabolic syndrome, so common among our psoriasis patients, drives up coronary artery disease in this population by increasing the plaque buildup that clogs the hearts arteries, said Nehal N. Mehta, M.D., MSCE, preventive cardiologist and head of the NHLBIs Lab of Inflammation and Cardiometabolic Diseases. Our study shows that, of the MetSyn components, hypertension and obesity contribute the most to coronary plaque buildup, and hence can be good targets for intervention.

Partly because it worsens vascular and systemic inflammation, psoriasis, a common skin disease affecting 2-3% of adults, not only increases but speeds up atherosclerosis, the plaque buildup that clogs arteries and can lead to heart attack and stroke. Metabolic syndrome affects about 25% of adults and is on the rise, and its prevalence is even greater among patients with psoriasis.

To reach their conclusions, Mehta and his team conducted an observational study of the NIH Psoriasis, Atherosclerosis, and Cardiometabolic Initiative cohort, which included 260 patients with psoriasis, 80 of whom met the criteria for metabolic syndrome. All participants underwent CT scanning to take pictures of their coronary arteries using a technique called cardiac computed tomography angiography (CTA).

The study found that systemic inflammation, insulin resistance, and blood cholesterol were significantly higher in the participants who had both psoriasis and metabolic syndrome. And those with MetSyn had higher coronary artery plaque buildup, assessed by CTA, which is a high-risk factor for heart attacks.

Even after adjusting for individual MetSyn factors, blood pressure and obesity assessed by waist circumference were the most significant links to coronary plaque buildup, Mehta explained.

Obesity is the most salient aspect of MetSyn, and excess visceral fat tissue, technically known as visceral adipose tissue (VAT), plays a large role in it, the researchers concluded after the amount of VAT measured by CT scans was associated to MetSyn factors such as waist circumference, blood pressure, triglycerides, high cholesterol.

VAT is a known predictor of cardiovascular disease in the general population, as well as a predictor of increased plaque buildup in psoriasis patients. However, due to the needed imaging technology, measuring VAT is not currently feasible in a doctors office.

This new study, Mehta said, demonstrates a critical link between excessive VAT and metabolic syndrome in psoriasis patients. It suggests that identifying metabolic syndrome, especially waist circumference, can significantly help in estimating VAT and assessing cardiovascular disease risk in clinical settings for patients with psoriasis.

It also showed for the first time, he said, the impact of metabolic syndrome on early vascular disease in psoriasis patients, measured through the plaque buildup.

In psoriasis patients, traditional risk factors of cardiovascular disease, such as age, do not relate strongly to cardiovascular risk as in the general population, Mehta said. However, he added, the findings in the study show the importance of evaluating for the presence of the metabolic syndrome as a heretofore unexplored risk factor.

Because this was an observational study, the researchers cannot establish cause-effect links, Mehta noted. But the new research provides strong evidence that psoriasis patients with metabolic syndrome have high levels of disease-producing plaque.

About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit http://www.nhlbi.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Mehta, N. et al.Metabolic Syndrome and its Factors are Associated with Non-Calcified Coronary Plaque Burden in Psoriasis: An Observational Cohort Study.DOI:

###

Continued here:
Study links metabolic syndrome to higher cardiovascular risk in patients with psoriasis - National Institutes of Health

Coherent Market Insights announced that its published an exclusive report namely Global Psoriasis Treatment Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Psoriasis Treatment Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.

Download FREE PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/99

The report presents an overview of Psoriasis Treatment Market consist of objectives study and definition of Psoriasis Treatment. The next section focuses on market size, region-wise Psoriasis Treatment growth rate estimation from 2020-2027.

This research report categorizes the global market by players/brands, regions, types, and applications. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, and Porters Five Forces Analysis.

Key Manufacturers Analysis:Glenmark Pharmaceuticals Limited, Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Johnson & Johnson, Rowan Bioceuticals Private Limited, Stiefel Laboratories Inc. (GlaxoSmithKline plc), Win Medicare Pvt. Ltd., and Novartis AG

The top manufacturers, exporters, and retailers (if applicable) around the world are analyzed for this research report with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Psoriasis Treatment Market 2020 Forecast to 2027 Market Segment by Regions, regional analysis covers

Following market aspects are enfolded in Global Psoriasis Treatment Market Report:

A wide summarization of the Global Psoriasis Treatment Market. The present and forecasted regional market size data based on applications, types, and regions. Market trends, drivers, and challenges for the Global Psoriasis Treatment Market. Analysis of company profiles of Top major players functioning in the market.

Buy This Research Study Report For Quick [emailprotected] https://www.coherentmarketinsights.com/insight/buy-now/99

Psoriasis Treatment Market report passes on a fundamental overview of the Market including its definition, applications, and advancement. Furthermore, the Industry report investigates the ecumenical Major Psoriasis Treatment Market players in detail. Psoriasis Treatment Market report gives key bits of the Cautiousness and subsisting status of the Players and is a basic Source obviously and heading for Companies and people energized by the Industry.

Key questions answered in Report:-

Psoriasis Treatment Business Analysis Including Size, Share, Key Drivers, Growth Opportunities and Trends 2020- 2027 Consumption Analysis of Psoriasis Treatment, Guidelines Overview and Upcoming Trends Forecast till 2027 Psoriasis Treatment Market Top Companies Sales, Price, Revenue and Market Share Outlook Psoriasis Treatment Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027 Analytical Overview, Growth Factors, Demand and Trends Psoriasis Treatment by Technology, Opportunity Analysis and Industry Forecasts, 2020- 2027 Analysis Covering Market Size, Growth Factors, Demand, Trends and Forecast Psoriasis Treatment Overview, Raw Materials Analysis, Market Drivers and Opportunities In-depth Research on Market Size, Trends, Emerging Growth Factors and Forecasts.

Conclusively, this report will provide you a clear view of each fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

****Stay Home. Stay Safe****

Read more from the original source:
Psoriasis Treatment Market to Witness an Outstanding Growth During 2020 2027 - Factory Gate

2020 was a significant year in rheumatology. Here are the top stories covered by DocWire News this year. Like last year, stories of interest were drug comparisons among medications treat rheumatic diseases; new to the top 10 are stories about the connection between rheumatic diseases and COVID-19, as well as ever-emerging research into how drugs used to treat rheumatic diseases may be repurposed for COVID-19 treatment.

This story makes the list for the second year in a row! In 2019, AbbVie announced that the Food and Drug Administration (FDA) approved its rheumatoid arthritis (RA) drug Rinvoq (upadacitinib). Rinvoq is an oral Janus kinase (JAK) inhibitor designed for the treatment of moderate to severe RA in patients who did not respond or have an intolerance to methotrexate. The company reported at the time that the JAK inhibitor would be available in the United States in August of 2019. Read on to see how DocWire compared Rinvoq to competitors fellow JAK inhibitors Olumiant and Xeljans, manufactured by Eli Lilly and Pfizer, respectively.

How Does AbbVies RA Drug Rinvoq Compare to Competitors?

There were a lot of stories on the connection between rheumatic diseases and COVID-19. One such study found that hospitalized COVID-19 patients with connective tissue diseases may be at risk for increased illness severity, but inflammatory arthritis may not have the same effect.

Do Inflammatory and Autoimmune Rheumatic Diseases Affect COVID-19 Illness Severity?

2019s reigning number one story comes in at number three this year. Following the FDAs approval of its approval of its osteoporosis drug romosozumab-aqqg (Evenity), Amgen announced the medication would be available in the United States at $1,825 per monthly dose, or $21,900 for a full, one-year course of treatment. Fellow bone-building competitors include Radius Health Inc.s Tymlos and Eli Lilly and Co.s Forteo, both of which also have longer courses of treatment. Read on to see how these three drugs compare in cost.

How Does Amgens Osteoporosis Drug EVENITY Compare to Competitors?

Respiratory viral infections may put patients at risk for developing RA, suggesting concerns for patients who develop coronavirus, according to a report published in August 2019 that resurfaced amid the current coronavirus pandemic. An association was observed between ambient respiratory viral infections in the population and an increase in incident RA over time, with a peak at six to seven weeks following exposure. The three viruses most associated with an increase in incident RA were parainfluenza virus (4.8% for 1% respiratory viral infection increase), coronavirus (9.2%), and metapneumovirus (44%). Patients who were impacted the most were women (3.8%, 12.1%, and 67.4%, respectively) and older patients (10.7%, 14.6%, and 118.2%, respectively).

Coronavirus May Be a Risk Factor for Rheumatoid Arthritis

Another veteran story from 2019. Last year, the FDA expanded the indication of Eli Lilly and Companys Taltz (ixekizumab) to include active ankylosing spondylitis (AS). The humanized interleukin-17A antagonist initially received approval in 2016 for the treatment of plaque psoriasis, and in 2017 of active psoriatic arthritis (PsA). It now competes with Novartis Cosentyx (secukinumab), which is indicated to treat the same three rheumatic diseases. Cosentyx garnered FDA approval in 2015 for the treatment of plaque psoriasis, and picked up the subsequent approvals for AS and PsA in 2016. Learn more here.

Taltz vs. Cosentyx: How Do These Rheumatic Drugs Compare?

Here are the five stories rounding out the top 10 list:

Go here to see the original:
The Top 10 Rheumatology Stories in 2020 - DocWire News

Both secukinumab 300 mg and secukinumab 150 mg significantly improved signs and symptoms of axial disease in patients with psoriatic arthritis (PsA) who had inadequate response to non- steroidal anti-inflammatory drugs.

Findings from a randomized controlled trial (RCT) are making the case for using secukinumab to treat axial disease in certain patients with psoriatic arthritis (PsA). Specifically, the trial found 2 doses of the interleukin (IL)-17A inhibitor yielded significant improvements in disease signs and symptoms.

The MAXIMISE (Managing AXIal Manifestations in psoriatic arthritis with SEcukinumab) trial was the first RCT to test a biological disease modifying anti-rheumatic drugs ability to improve outcomes in axial manifestations of PsA. All patients previously had inadequate responses to at least 2 non-steroidal anti-inflammatory drugs over a 4-week period.

The axial involvement represents an unmet clinical need in determining the treatment strategy across all PsA manifestations and ultimately supports informed treatment decision-making, wrote the researchers. Additionally, patients with PsA tend to under-report axial symptoms and consequently the burden of disease might be underestimated for axial disease in such patients. As a consequence, the efficacy of a biological treatment in managing axial symptoms in PsA has been investigated only in two observational studies to date, and never in a randomized controlled setting.

A total of 425 patients completed the 52-week MAXIMISE study and received placebo or either secukinumab 300 mg or secukinumab 150 mg, both of which significantly improved responses compared with placebo after 12 weeks of treatment (63% and 66%, respectively, vs 31%).

Compared with placebo, the odds ratio of having an improved response as determined by the Assessment of SpondyloArthritis International Society (ASAS20)defined as an improvement of 20% and 1 unit on a scale of 10 in at least 3 of the 4 main ASAS domainswas 3.8 for patients receiving secukinumab 300 and 4.4 for patients receiving secukinumab 150 mg.

Responses rates for patients receiving secukinumab 300, secukinumab 150 mg, or switching from placebo to either secukinumab dose were 81%, 80%, and 75%, respectively. The responses were durable, researchers found, with patients sustaining responses through the end of the study.

In addition, MRI assessments demonstrated that secukinumab 300 mg and 150 mg significantly improved Berlin MRI scores versus placebo, providing objective evidence of reduced inflammation in both the spine and the [sacroiliac joints] for patients treated with secukinumab, authors wrote.

Researchers observed comparable types and incidences of adverse events between the monoclonal antibody and placebo. No notable differences were seen between the 2 secukinumab doses.

Reference: Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. Published online December 17, 2020. doi:10.1136/annrheumdis-2020-218808

See more here:
Secukinumab Improves Signs, Symptoms of Axial Disease in Patients With PsA - AJMC.com Managed Markets Network